Mironid®‘s unique approach

Mironid, through its world leading expertise in the biochemistry and structure-function relationships of PDE4, has developed proprietary knowledge that has unlocked the ability to develop subtype-selective PDE4 inhibitors, with the potential to negate the gastro-intestinal side effects that have plagued the field and limited the use of approved pan-PDE4 therapies. In addition, Mironid have identified the very first discovery of PDE4 activators that will allow the targeting of diseases driven by aberrantly elevated cyclic AMP levels, such as autosomal dominant polycystic disease (ADPKD).

An ambitious, vibrant, growing, customer-centric company

get in touch